



# An efficient, enantioselective synthesis of branched polyhydroxylated pyrrolidines<sup>†</sup>

Mark F. Mechelke and A. I. Meyers\*

*Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA*

Received 2 August 2000; revised 28 August 2000; accepted 29 August 2000

---

## Abstract

The enantioselective synthesis of branched polyhydroxylated pyrrolidines from a novel  $\alpha$ -methylene bicyclic lactam (**4b**) is described. © 2000 Elsevier Science Ltd. All rights reserved.

---


Polyhydroxylated pyrrolidines have generated a great deal of synthetic interest in the past decade due to their structural resemblance to the sugar moiety of monosaccharides.<sup>1</sup> Because of their ability to mimic carbohydrates, they function as potent inhibitors of glycosidases; enzymes that are involved in a wide range of important biological processes.<sup>2</sup> The discovery that these sugar mimetics display considerable activity against cancer,<sup>3</sup> diabetes,<sup>1</sup> and viral infections (anti-HIV behavior)<sup>4</sup> has led to an enhanced interest in them as potential therapeutic agents. Recently, the syntheses of novel polyhydroxylated piperidines, **1**, and pyrrolidines, (+)-**2**, containing branched skeletons<sup>5</sup> (Scheme 1) have been reported in an attempt to develop more selective and potent glycosidase inhibitors. Due to our previous success in preparing azasugars from bicyclic lactams<sup>6</sup> and our continued effort in expanding the versatility of this chiral molecule, we anticipated that the synthesis of branched polyhydroxylated pyrrolidines, **2**, could be achieved in high enantiomeric purity from an appropriately functionalized 5,5-bicyclic lactam (**4b**).

It was envisioned that bicyclic lactam **4b**, possessing an  $\alpha$ -methylene substituent, could be accessed from the known lactam **3b**.<sup>6</sup> The olefin, **4b**, would be subjected to dihydroxylation conditions to afford diol **5b**—hopefully with some degree of *exo-endo* selectivity. Reductive cleavage of **5b**, after diol protection, would complete an efficient synthesis of pyrrolidine **6**. The latter could be further elaborated to azasugars such as **2**, with the option of placing a variety of substituents ( $R^2$ ) on the nitrogen atom.

---

\* Corresponding author.


<sup>†</sup> This paper is dedicated with respect and admiration to Professor Harry Wasserman on his 80th birthday.



Scheme 1.

The route to **2** and **6** began with the preparation of known bicyclic lactam **3b**<sup>6</sup> from 2,3-dihydrofuran in 47% yield over three steps. Readily available lactam **3a**,<sup>7</sup> containing an angular methyl substituent, was also prepared and employed as a model. Attention was then turned toward the introduction of the  $\alpha$ -methylene substituent. Although a variety of methods to prepare  $\alpha$ -methylene lactones are known,<sup>8</sup> all attempts to use these met with failure or limited success. Diez and co-workers<sup>9</sup> reported similar difficulties in preparing chiral  $\alpha$ -methylene 2-piperidones. In an effort to avoid these problems, the enolate anions of both lactams **3a** and **3b** were treated with diethyl phosphorochloridite<sup>10</sup> followed by immediate air oxidation of the resultant reaction products (Scheme 2). In both cases (lactams **7a** and **7b**), the <sup>31</sup>P NMR spectra of the crude reaction mixtures revealed a 2.5:1 ratio of C–P to O–P bond formation products—the C–P products being a mixture of *exo*–*endo* diastereomers (3:1). This crude mixture was treated with NaH followed by paraformaldehyde to provide a 43% yield (55% yield based on recovered starting material) of the desired  $\alpha$ -methylene bicyclic lactams **4a** and **4b** over the two steps.

Initial experiments to introduce vicinal hydroxyls were performed on lactam **4a**, which was treated with OsO<sub>4</sub>–NMO to furnish a disappointing 3:1 (NMR) mixture of diastereomers (Table 1). In order to increase the selectivity of the dihydroxylation, quinuclidine was added as a ligand since it was anticipated that the ligand–OsO<sub>4</sub> complex<sup>11</sup> would provide increased facial selectivity due to its greater steric bulk as compared to OsO<sub>4</sub> alone. The selectivity did increase, providing a 7:1 mixture of diastereomers at the newly formed tertiary alcohol center (diol **5a**). Attention was now turned to bicyclic lactam **4b**. Treatment of **4b** with OsO<sub>4</sub>–quinuclidine, however, gave a poor mixture of diastereomers (3:1) as compared to the model system (7:1). This result suggested that the dihydroxylation might be occurring preferentially from the *exo*-face; the decrease in *exo*-facial selectivity with lactam **4b** perhaps arising from the larger angular benzyloxymethyl substituent shielding the  $\beta$ -face of the lactam. It was felt that the addition of a ligand bulkier than quinuclidine might improve the facial selectivity of the dihydroxylation. Lactam **4b** was subsequently treated with AD-mix- $\alpha$  and AD-mix- $\beta$ , respectively<sup>11</sup> providing a greater than 15:1 (NMR) mixture of diastereomers. It is interesting to note that in the reactions using either AD-mix- $\alpha$  or AD-mix- $\beta$ , the same ratio of diastereomers was observed (15:1) with the same sense of stereochemistry. This strongly suggests that the



Scheme 2.

Table 1


Lactam	Ligand	de	Yield (%)
<b>4a</b>	–	3:1	89
<b>4a</b>	Quinuclidine	7:1	96
<b>4b</b>	Quinuclidine	3:1	93
<b>4b</b>	AD-mix- $\alpha$	15:1	98
<b>4b</b>	AD-mix- $\beta$	15:1	100

increase in the observed facial selectivity is not due to the chirality of these ligands, but is due solely to their steric bulk. The stereochemistry of the dihydroxylation products **5**, were tentatively assigned, at this point, as taking place from the *exo*-face.

The two hydroxyl groups were transformed to their benzyl ethers, **8**, and the C–O cleavage step was next addressed to prepare pyrrolidine **9**. From earlier results in our laboratory,<sup>12</sup> it was anticipated that this reaction would proceed with retention of configuration of the angular substituent. Thus, treatment of **8** with DIBAL-H furnished an 88% yield of pyrrolidine **9**; the reductive cleavage of the ring C–O bond occurring with very high diastereoselectivity (no trace of C-2 diastereomers being observed). The 15:1 mixture of diastereomers obtained from the dihydroxylation could also be separated by column chromatography at this point, providing compound **9** as a single diastereomer. The stereochemistry at C-2 was tentatively assigned as

having occurred with retention of configuration. Catalytic hydrogenation ( $\text{H}_2$ , 4 atm,  $\text{Pd}(\text{OH})_2$ ) in the presence of  $\text{Boc}_2\text{O}$  afforded branched pyrrolidine **6**, which was immediately acetylated to provide **10** in 68% yield. It is interesting to note that if  $\text{Boc}_2\text{O}$  is not added to the hydrogenation, only *N*-benzyl deprotection is observed and the *O*-benzyl groups remain intact.<sup>13</sup> Pyrrolidine **10** provides a convenient entry into branched pyrrolidines, because by simply treating **10** with TFA in  $\text{CH}_2\text{Cl}_2$ , the Boc protecting group can be removed (pyrrolidine **11**), leaving the nitrogen free to react with any number of electrophiles. The ease at which **10** is transformed into *N*-benzylated pyrrolidine **2** illustrates the usefulness of this intermediate.

With an efficient, enantioselective synthesis of pyrrolidine **10** in hand (ten steps from 2,3-dihydrofuran, 12% overall yield), it was necessary to confirm the absolute configuration. Commercially available (*S*)-(+)-5-(hydroxymethyl)-2-pyrrolidinone **12** was dibenzylated to afford pyrrolidinone **13** in 80% yield (Scheme 3). The latter was olefinated [LDA/(EtO)<sub>2</sub>PCl, air, NaH/(CH<sub>2</sub>O)<sub>n</sub>] to the  $\alpha$ -methylene lactam **14** in 65% yield. Dihydroxylation of **14** employing OsO<sub>4</sub>-NMO gave a 2.5:1 (NMR) mixture of diastereomers (diol **15**). Similar results were obtained using quinuclidine. Surprisingly, addition of AD-mix- $\alpha$  or AD-mix- $\beta$  decreases the diastereoselectivity, affording a 1:1 ratio of diastereomers. It was assumed that the major product in the OsO<sub>4</sub>-NMO dihydroxylation arose from  $\alpha$ -facial selectivity; the *trans* product being favored due to shielding of the  $\beta$ -face by the benzyloxymethyl C-5 substituent. Dibenzylation of the diol moiety followed by a DIBAL-H reduction furnished the tetrabenzyl pyrrolidine **17** in high yield. Hydrogenolyses of the *N*-benzyl and *O*-benzyl groups in the presence of  $\text{Boc}_2\text{O}$  afforded **18**, which was immediately acetylated to provide pyrrolidine **19** as a 3:1 mixture of diastereomers. When the <sup>1</sup>H NMR spectrum of pyrrolidine **19** was compared to the <sup>1</sup>H NMR spectrum of pyrrolidine **10** prepared via the bicyclic lactam route, it became apparent that the minor diastereomer of **19** was identical to **10**. With the absolute configuration of **19** known, this sequence proved the relative stereochemistry of **10**, with the acetoxymethyl substituents lying *anti* to each other. Since (+)-**2** had previously been prepared in the literature,<sup>5b</sup> to confirm the absolute configuration of **10**, it only became necessary to determine the stereochemistry of **2** prepared from **10** above ( $[\alpha]_D$  lit. =



Scheme 3.

+30.0,<sup>14</sup>  $[\alpha]_{\text{D}}$  of **2** = -44.2). The negative optical rotation observed for **2** proved that the stereochemical assignment was correct, with the dihydroxylation proceeding from the *exo*-face and the C–O ring reduction occurring with retention of configuration to afford (-)-**2**.

In conclusion, an efficient, enantioselective route to branched, *N*-substituted pyrrolidines has been accomplished using chiral bicyclic lactams. A convenient entry into branched pyrrolidines is now available using intermediate **10**, which may be elaborated in a variety of ways.

## Acknowledgements

The authors thank Merck for a post-doctoral fellowship (to M.F.M.) and the National Institutes of Health for financial support.

## References

1. (a) Baxter, E. W.; Reitz, A. B. *J. Org. Chem.* **1994**, *59*, 3175. (b) Sinnott, L. M. *Chem. Rev.* **1990**, *90*, 1171.
2. Asano, N.; Nash, R. J.; Molyneux, R. J.; Fleet, G. W. *J. Tetrahedron: Asymmetry* **2000**, *11*, 1645.
3. (a) Bernaki, R. J.; Korytnyk, W. *Cancer Metastasis Rev.* **1985**, *4*, 81. (b) Tsukamoto, K. et al. *Clin. Res.* **1989**, *37A*, 722.
4. (a) Fleet, G. W. J. et al; *FEBS Lett.* **1998**, 237. (b) Gruters, R. A.; Niefies, J. J.; Tersmette, M. I.; DeGroede, R. E.; Tulp, A.; Heisman, H. G.; Miedema, F.; Ploegh, H. L. *Nature* **1987**, *330*, 74.
5. (a) Ichikawa, M.; Igarashi, Y.; Ichikawa, Y. *Tetrahedron Lett.* **1995**, *36*, 1767. (b) Bennis, K.; Gelas, J.; Thomassigny, C. *Carbohydr. Res.* **1995**, *279*, 307.
6. Meyers, A. I.; Andres, C. J.; Resek, J. E.; Woodall, C. C.; McLaughlin, M. A.; Lee, P. H.; Price, D. A. *Tetrahedron* **1999**, *55*, 8931.
7. Romo, D.; Meyers, A. I. *Tetrahedron* **1991**, *47*, 9503.
8. Grieco, P. A. *Synthesis* **1975**, 67 and references cited therein.
9. Forns, P.; Fernandez, M. M.; Diez, A.; Rubiralta, M.; Cherrier, M. P.; Bonin, M.; Quirion, J.-C. *Synthesis* **1999**, 258.
10. Lee, K.; Wiemer, D. F. *J. Org. Chem.* **1991**, *56*, 5556.
11. Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483.
12. Meyers, A. I.; Burgess, L. E. *J. Org. Chem.* **1991**, *56*, 2294.
13. Czech, B. P.; Bartsch, R. A. *J. Org. Chem.* **1984**, *49*, 4076.
14. The  $[\alpha]_{\text{D}}$  value of our sample, -44.2, does not compare well to the literature value, +30.0, because their compound was contaminated with trace amounts of another undetermined isomer—see Ref. 5b.